Latus Bio key facts
- Developer of curative medicines designed for neurological diseases.
- It has raised $87.5M; the latest was Early Stage VC ($33.5M) in Aug 2025.
- Notable investors include Gaingels, 8VC, Calm Ventures, Korea Development Bank, Samsung Venture Investment — 12 tracked in total.
- Status: Privately Held (backing).
Who backs Latus Bio
12+- ·The complete investor list: 12 names
- ·Watch Latus Bio: the Monday email on marks, rounds and moves
Latus Bio funding rounds
No funding rounds for Latus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Latus Bio investors
12 investors are on record for Latus Bio, including Gaingels, 8VC, Calm Ventures and Korea Development Bank. By type, the record holds 6 venture capital firms.
About Latus Bio
Developer of curative medicines designed for neurological diseases. The company specializes in novel non-human primate-based discovery approaches, enabling doctors to deliver therapeutic genes to targeted cells with increased substructure- and cell-specific targeting in the central nervous system.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2022
- Employees
- 31
- Website
- latusbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Latus Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.